A Digital Therapeutic for Pain Relief through AI-Guided Visual Stimulation

通过人工智能引导视觉刺激缓解疼痛的数字疗法

• 批准号: 10325724
• 负责人: Adam Hanina
• 金额: $ 31.95万
• 依托单位: DANDELION SCIENCE CORP
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325724
• 关键词: American; Artificial Intelligence; Behavioral; Biofeedback; Biosensor; Brain; Cellular Phone; Clinical; Cognitive Therapy; Color; Complex; Computer software; Data; Electrocardiogram; Electroencephalogram; Ensure; Eye; Feedback; Frequencies; Goals; Intervention; Licensing; Magnetism; Maps; Marketing; Meditation; Mental disorders; Methods; Opioid; Opioid Analgesics; Outcome; Pain; Pain intensity; Pain management; Patients; Pattern; Perception; Pharmacologic Substance; Pharmacology; Phase; Photic Stimulation; Physiological; Process; Randomized Controlled Trials; Reproducibility; Research Personnel; Secure; Services; Signal Transduction; Small Business Innovation Research Grant; Stimulus; Symptoms; System; Tablets; Taraxacum; Technology; Testing; Therapeutic; Therapeutic Effect; Time; Treatment Efficacy; Visual; Writing; analog; base; clinical pain; commercial application; complex data; computational neuroscience; computerized data processing; cost; deep learning; design; digital; digital treatment; distraction; mobile computing; nervous system disorder; neuroregulation; novel; opioid mortality; opioid sparing; pain perception; pain reduction; pain relief; prototype; relating to nervous system; response; therapy design; visual information; visual stimulus; wearable sensor technology

PROJECT SUMMARY Dandelion™ was founded in 2020 to develop digital therapeutics for neurologic and psychiatric disorders by interacting with the brain via the eyes. The goal of this SBIR is to design and test a safe, effective, and non- addictive pain-relief digital therapeutic in the form of visual stimuli. The platform will use artificial intelligence (AI) and real-time biofeedback to “read” (decipher) brain signals and “write” to (neuromodulate) the brain with rapid-changing visual stimuli composed of optimized patterns, colors, and frequencies. This is the first attempt to use AI-guided visual stimuli as a treatment for pain. In 2017, 11 million of the 191 million prescriptions written for opioid pain medications were misused, and 35% of opioid-related deaths (nearly 17,000 cases) were connected to these prescriptions. In the search for safe, effective alternatives, a range of opioid-sparing interventions have been developed through pharmacologic, clinical, and digitized behavioral platforms but none has proved fully successful. Dandelion hypothesizes that the complexity and variability of pain demands a therapeutic approach that mimics the way the brain itself processes and integrates data for pain perception. Through its novel neuromodulatory platform, using artificial intelligence to parameterize potentially useful visual information, Dandelion will develop a safe, low-cost digital therapeutic that patients can view on a smartphone or tablet for immediate pain relief. By correlating stimulus with response across different types of pain, Dandelion also hopes to build a pain-perception map of wider applicability. In Phase I a prototype AI-guided platform will be developed that can synthesize novel stimulation combinations and optimize them based on feedback from an array of biosensors; their efficacy in reducing the perception of induced pain will then be tested in healthy subjects. In Phase II, Dandelion will develop the prototype into a commercially available product and test the pain-relief digital therapeutic for efficacy and generalizability in randomized controlled trials. The commercial opportunity is estimated to be $5.9 billion.

项目概要 Dandelion™ 成立于 2020 年，致力于开发针对神经和精神疾病的数字疗法 通过眼睛与大脑互动。该 SBIR 的目标是设计和测试安全、有效且非 以视觉刺激形式进行的令人上瘾的止痛数字治疗。该平台将使用人工智能 （人工智能）和实时生物反馈来“读取”（破译）大脑信号并“写入”（神经调节）大脑 由优化的图案、颜色和频率组成的快速变化的视觉刺激。这是第一次尝试 使用人工智能引导的视觉刺激来治疗疼痛。 2017年，1.91亿张处方中，有1100万张 为阿片类止痛药编写的药物被滥用，35% 的阿片类药物相关死亡（近 17,000 例） 与这些处方有关。在寻找安全、有效的替代品时，一系列阿片类药物 干预措施是通过药理学、临床和数字化行为平台开发的，但 没有一个被证明是完全成功的。蒲公英假设疼痛的复杂性和可变性需要 一种模仿大脑本身处理和整合疼痛感知数据的方式的治疗方法。 通过其新颖的神经调节平台，利用人工智能来参数化潜在有用的视觉 信息显示，Dandelion 将开发一种安全、低成本的数字疗法，患者可以在智能手机上查看 或立即缓解疼痛的药片。通过将刺激与不同类型疼痛的反应相关联， 蒲公英还希望建立一个具有更广泛适用性的疼痛感知图。第一阶段是人工智能引导的原型 将开发平台，可以合成新颖的刺激组合并基于 来自一系列生物传感器的反馈；它们在减少诱发疼痛感知方面的功效将是 在健康受试者中进行测试。在第二阶段，Dandelion 将把原型开发成商用产品 产品并在随机对照中测试止痛数字疗法的功效和普遍性 试验。商业机会估计为 59 亿美元。